文献リスト

1) Yokoyama H, Kawai K, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care. 2007; 30: 989-92

2) Wu AYT, Kong NCT, de Leon FA, et al; for the MAPS investigators. An alarming high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005; 48: 17-26

3) Parving HH, Lewis JB, Ravid M, et al. DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006; 69: 2057-63

4) Yokoyama H, Sone H, Oishi M, et al; Japan Diabetes Clinical Data Management Study Group. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2009; 24: 1212-9

5) Yokoyama H, Oishi M, Kawai K, et al; Japan Diabetes Clinical Data Management Study Group. Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in Type 2 diabetes: JDDM study 16. Diabet Med. 2008; 25: 1426-32

6) Kimura T, Ikeda H, Fujikawa J, et al. Usefulness of serum cystatin C in Japanese patients with type 2 diabetes mellitus and nephropathy. Diabetes Res Clin Pract. 2009; 83: e58-61

7) Sone H, Tanaka S, Iimuro S, et al; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010; 53: 419-28

8) Katakura M, Naka M, Kondo T, et al. Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects: Nagano study. Diabetes Care. 2003; 26: 638-44

9) Tanaka Y, Daida H, Imai Y, et al. Morning home blood pressure may be a significant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1. Hypertens Res. 2009; 32: 770-4

10) Saito K, Sone H, Kawai K, et al. Risk imparted by various parameters of smoking in Japanese men with type 2 diabetes on their development of microalbuminuria: analysis from the Tsukuba Kawai Diabetes Registry. Diabetes Care. 2007; 30: 1286-8

11) Yamada T, Komatsu M, Komiya I, et al. Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa study. Diabetes Care. 2005; 28: 2733-8

12) Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001; 54: 191-201

13) Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007; 30: 1581-3

14) Makino H, Haneda M, Babazono T, et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res. 2005; 33: 677-86

15) McCarty CA, Harper CA, Taylor HR. Long-trem complications: Diabetic Retinopathy. In: Ekoe JM, Zimmet P, Williams R, editors. The Epidemiology of Diabetes Mellitus. An International Perspectives. John Wiley & Sons; Oxford: 2001. p.349-68

16) Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010; 304: 649-56

17) Anan F, Masaki T, Ito Y, et al. Diabetic retinopathy is associated with visceral fat accumulation in Japanese type 2 diabetes mellitus patients. Metabolism. 2010; 59: 314-9

18) 佐藤 譲, 馬場正之, 八木橋操六, 他, 東北糖尿病合併症フォーラムプロジェクト会. 糖尿病神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義 ―東北地方15000人の実態調査―. 糖尿病. 2007; 50: 799-806

19) Osawa H, Doi Y, Makino H, et al. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol. 2009; 8: 60

20) Song J, Sumiyoshi S, Nakashima Y, et al. Overexpression of heme oxygenase-1 in coronary atherosclerosis of Japanese autopsies with diabetes mellitus: Hisayama study. Atherosclerosis. 2009; 202: 573-81

21) Hirota T, Suzuki E, Ito I, et al. Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels of tumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2008; 82: 58-65

22) Hashimoto K, Ikewaki K, Yagi H, et al. Glucose intolerance is common in Japanese patients with acute coronary syndrome who were not previously diagnosed with diabetes. Diabetes Care. 2005; 28: 1182-6

23) Urabe T, Watada H, Okuma Y, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke. 2009; 40: 1289-95

24) Hayashino Y, Shimbo T, Tsujii S, et al. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines. Int J Cardiol. 2007; 118: 88-96

25) Asia Pacific Cohort Studies Collaboration. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia. 2007; 50: 2289-97

26) Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371: 117-25

27) Hayashi T, Kawashima S, Itoh H, et al; on behalf of Japan CDM group. Low HDL-cholesterol is associated with the risk of stroke in elderly diabetic individuals: Changes in the risk for atherosclerotic diseases at various ages. Diabetes Care. 2009; 32: 1221-3

28) Tajima N, Kurata H, Nakaya N, et al; Primary Prevention Group of Adult Japanese (MEGA) Study. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis. 2008; 199: 455-62

29) Oikawa S, Yokoyama M, Origasa H, et al; JELIS Investigators, Japan. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2009; 206: 535-9

30) Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010; 121: 2694-701

31) Ogawa H, Nakayama M, Morimoto T, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300: 2134-41

32) Katakami N, Kim YS, Kawamori R, et al. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation. 2010; 121: 2584-91

33) Matsumoto K, Sera Y, Nakamura H, et al. Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism. 2002; 51: 244-7

34) Nomura K, Hamamoto Y, Takahara S, et al. Relationship between carotid intima-media thickness and silent cerebral infarction in Japanese subjects with type 2 diabetes. Diabetes Care. 2010; 33: 168-70

35) Sone H, Tanaka S, Iimuro S, et al. Waist circumference as a cardiovascular and metabolic risk in Japanese patients with type 2 diabetes. Obesity. 2009; 17: 585-92

36) Sone H, Mizuno S, Fujii H, et al; Japan Diabetes Complications Study. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients？ Analysis from the Japan Diabetes Complications Study. Diabetes Care. 2005; 28: 1463-71

37) Sone H, Tanaka S, Ishibashi S, et al; Japan Diabetes Complications Study (JDCS) Group. The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions: additional analysis from the Japan Diabetes Complications Study. Diabetes Care. 2006; 29: 145-7

38) Cull CA, Jensen CC, Retnakaran R, et al. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation. 2007; 116: 2119-26

39) Sone H, Tanaka S, Iimuro S, et al. Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes. Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS). J Atheroscler Thromb. 2009; 16: 380-7

40) Araki A, Murotani Y, Kamimiya F, et al. Low well-being is an independent predictor for stroke in elderly patients with diabetes mellitus. J Am Geriatr Soc. 2004; 52: 205-10

41) Tsukahara T, Nakashima E, Watarai A, et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2009; 84: 179-86

42) Katakami N, Takahara M, Kaneto H, et al. Accumulation of gene polymorphisms related to plaque disruption and thrombosis is associated with cerebral infarction in subjects with type 2 diabetes. Diabetes Care. 2010; 33: 390-5

43) Tamemoto H, Ishikawa SE, Kawakami M. Association of the Glu298Asp polymorphism of the eNOS Gene with ischemic heart disease in Japanese diabetic subjects. Diabetes Res Clin Pract. 2008; 80: 275-9

44) Ohshige T, Tanaka Y, Araki S, et al. A single nucleotide polymorphism in KCNQ1 is associated with susceptibility to diabetic nephropathy in japanese subjects with type 2 diabetes. Diabetes Care. 2010; 33: 842-6

45) Mokubo A, Tanaka Y, Nakajima K, et al. Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetes Res Clin Pract. 2006; 73: 89-94

46) Yoshioka K, Yoshida T, Takakura Y, et al. Relationship between polymorphisms 804C/A and 252A/G of lymphotoxin-alpha gene and -308G/A of tumor necrosis factor alpha gene and diabetic retinopathy in Japanese patients with type 2 diabetes mellitus. Metabolism. 2006; 55: 1406-10

47) Maeda M, Yamamoto I, Fukuda M, et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complications. 2008; 22: 119-25

48) Nakanishi K, Watanabe C. Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. Clin Chim Acta. 2009; 402: 171-5

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp